Preliminary Fourth Quarter 2018 Highlights: Fourth quarter 2018 reported revenue is expected to be at the higher end of the company’s previous guidance range of $378 million to $383 million; Organic revenue growth in the fourth quarter 2018 is expected to be slightly above 4%.

PLAINSBORO, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced President and Chief Executive Officer Peter Arduini will speak at the 37 th Annual J.P.

PLAINSBORO, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced one of the first surgeries with the Integra® XT Revision Total Ankle Replacement System.

PLAINSBORO, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Eric Schwartz as corporate vice president, general counsel and secretary.   “I am pleased to welcome Eric as our new general counsel and latest member of

PLAINSBORO, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conference in October: On Thursday, November 15, 2018 at 9:10 a.m.

Revenue Increased 31.2% to $365.9 million; Organic Revenue Increased 6.2% Reported EPS of $0.15; Adjusted EPS of $0.59 Revises Full-Year 2018 Revenue Guidance to $1.467 Billion to $1.472 Billion and Organic Revenue Growth to Approximately 4% PLAINSBORO, N.J., Oct.

PLAINSBORO, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2018 financial results on Wednesday, October 31, 2018, prior to market open.

PLAINSBORO, N.J., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conference in October: On Monday, October 1, 2018 at 4:05 p.m.

PLAINSBORO, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced it has been selected as a primary provider for cellular-based tissue products within Healogics ® Inc. new iSupply program.

PLAINSBORO, N.J., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in September: On Thursday, September 6, 2018 at 8:35 a.m.

Tokyo, Japan, July 23, 2018 - Integra LifeSciences Holdings Corporation (Nasdaq: IART ), a global leader in medical technology, announces the launch of its new CUSA ® Clarity ultrasonic tissue ablation platform in Japan. The system was launched in North America and Europe and has gained significant

Revenue Increased 29.8% to $366.2 million; Organic Revenue Increased 3.4%  Reported EPS of $0.14; Adjusted EPS of $0.60 Raises Low-End of Full-Year Total Revenue and EPS Guidance Successfully Exits First Wave of Codman Transition Services Agreements PLAINSBORO, N.J., July 25, 2018 (GLOBE NEWSWIRE)

PLAINSBORO, N.J., July 11, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2018 financial results on Wednesday, July 25, 2018, prior to market open.

PLAINSBORO, N.J. , May 23, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the following healthcare conferences in June: On Wednesday, June 6, 2018 at 3:30 p.m.

PLAINSBORO, N.J. , May 09, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has priced its previously announced underwritten public offering of 5,250,000 shares of its common stock at $58.50 per